<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/311">
    <title>Repository Community: null</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/311</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61179" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61177" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61059" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/57680" />
      </rdf:Seq>
    </items>
    <dc:date>2026-11-21T08:00:14Z</dc:date>
  </channel>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61179">
    <title>Sunitinib induces senolysis associated with modulation of platelet-derived growth factor receptor beta</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61179</link>
    <description>Title: Sunitinib induces senolysis associated with modulation of platelet-derived growth factor receptor beta
Author(s): Cho, Hyun-Ji; Ryu, Sung Jin; Kim, Byung Ju; Hwang, Jeong-A; Yun, Ahyeon; Kim, Eok-Cheon; Kim, Jae-Ryong; Park, Tae Jun; Lee, Sung Bae; Kim, Young Zoon; Lee, Yun-Il; Park, Sang Chul; Lee, Young-Sam
Abstract: Receptor tyrosine kinases are critical regulators of cell survival, mediating responses to environmental changes and maintaining biological responsiveness. However, despite growing interest in developing senolytics that target survival factors in senescent cells as a promising strategy to overcome age-related diseases, the therapeutic potential of RTKs in senescence remains largely unexplored. In this study, we aimed to identify senolytic compounds that modulate RTK signaling and ameliorate age-related phenotypes by selectively inducing senescent cell death. Using a drug screening approach, we identified sunitinib, a multi-targeted RTK inhibitor that effectively suppresses PDGFR activation and induces apoptosis specifically in senescent HDFs (sHDFs) by activating caspase-9, −3, and −7. Moreover, in a mouse model of bleomycin-induced lung fibrosis in which senescent cells accumulate in the tissue, sunitinib reduced senescent cells and suppressed SASP expression. These findings, together with the observed increase in PDGFRβ phosphorylation in aged cells, led us to hypothesize that modulating PDGFRβ activity could induce senolysis. Indeed, knockdown of PDGFRβ expression sensitized senescent cells to cell death, with minimal effects on non-senescent HDFs (nsHDFs). At the mechanistic level, PDGFRβ and its downstream pathways, including the JAK2-STAT3 pathway, contributed to the senolytic response to sunitinib. Notably, sunitinib-induced JAK1 phosphorylation contributed to resistance to sunitinib in nsHDFs. Our findings suggest that sunitinib is a promising senolytic agent and that targeting PDGFRβ may represent a previously unknown approach to senolytics. Therefore, our study may provide a potential therapeutic strategy for age-related diseases associated with chronic inflammation.</description>
    <dc:date>2026-10-31T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61177">
    <title>Cytoplasmic TDP-43 aggregation promotes oxidative stress and neurotoxicity through Trx1 mRNA sequestration and translational suppression</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61177</link>
    <description>Title: Cytoplasmic TDP-43 aggregation promotes oxidative stress and neurotoxicity through Trx1 mRNA sequestration and translational suppression
Author(s): Lee, Ji Min; Bok, Eugene; Jeon, Hyeonjin; Hwang, Seonhyeok; Hong, Jiwon; Lee, Sung Bae; Cha, Sun Joo; Kang, Soo Hyun; Kim, Hyung-Jun; Cheon, Mookyung; Lee, Byung-Hoon; Kim, Chuna; Lee, Sang-Won; Kim, Sang Ryong; Nahm, Minyeop; Kim, Jaekwang
Abstract: Transactive response (TAR) DNA-binding protein 43 (TDP-43) is a multifunctional DNA/RNA binding protein. Cytoplasmic TDP-43 aggregation is a pathological hallmark of diverse neurodegenerative diseases collectively termed TDP-43 proteinopathy. Oxidative stress is closely associated with TDP-43 aggregation and neurotoxicity in TDP-43 proteinopathy, yet the underlying molecular mechanisms remain elusive. To delineate molecular basis of TDP-43 proteinopathy, we conducted deep quantitative proteomic profiling using a Neuro-2a (N2a) neuronal cell model of human wild-type TDP-43 overexpression (N2a-hTDP-43). We identified thioredoxin-1 (Trx1) as a central node linking mitochondrial dysfunction and redox dysregulation to TDP-43 pathology. Consistent with this, TDP-43 overexpression markedly reduced Trx1 protein levels. Moreover, inhibiting Trx1 exacerbates, whereas overexpressing Trx1 alleviates, cytoplasmic TDP-43 aggregation and neurotoxicity in N2a-hTDP-43 cells. Furthermore, overexpressing Trx1 alleviates TDP-43-associated pathologies in mouse primary neurons. Notably, we identified that cytoplasmic TDP-43 protein sequesters Trx1 mRNAs into insoluble TDP-43 inclusions, leading to its translational suppression. We also demonstrated that suppression of Trx1 is a core mechanism eliciting oxidative stress and mitochondrial dysfunction in TDP-43 overexpression model. Importantly, in human induced pluripotent stem cell (iPSC)-derived motor neurons (MN) harboring the pathogenic TDP-43 M337V mutation (TDP-43M337V iPSC-MNs), Trx1 expression is downregulated, concomitant with increased oxidative stress, compared to the isogenic TDP-43WT iPSC-MN control. Furthermore, inducing Trx1 expression markedly reduces oxidative stress and cytoplasmic TDP-43 aggregation in TDP-43M337V iPSC-MNs, suggesting conserved neuroprotective role of Trx1 in TDP-43 proteinopathy in human. Collectively, we identified Trx1 as a pivotal regulator of TDP-43 proteinopathy, highlighting therapeutic potential of Trx1 for TDP-43 proteinopathies.</description>
    <dc:date>2026-11-30T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61059">
    <title>Alzheimer’s disease through the lens of mesenchymal drift: the collapse of cellular identity</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61059</link>
    <description>Title: Alzheimer’s disease through the lens of mesenchymal drift: the collapse of cellular identity
Author(s): Jeon, Juyeong; Yu, Jichang; Lee, Sung Bae; Seo, Jinsoo
Abstract: Cellular identity is maintained by precise epigenetic regulation, but chronic stress and aging can disrupt this control, leading to mesenchymal drift (MD). Unlike the coordinated process of epithelial-mesenchymal transition (EMT), MD is a stochastic, lineage-independent phenomenon marked by increased epigenetic noise and the widespread activation of profibrotic gene programs. As originally defined, MD requires two components to co-occur: a compromised original cellular identity together with the acquisition or intensification of mesenchymal traits. Applying the MD framework to Alzheimer's disease (AD) provides a new perspective on its pathogenesis. In AD, brain cells do not merely survive or die due to protein toxicity; instead, they lose their specialized identities in an uncoordinated fashion. This transcriptomic drift has been reported across major cell types in the central nervous system: neural progenitor cells differentiate prematurely, mature neurons undergo transcriptomic dedifferentiation, endothelial cells develop features of vascular fibrosis, and glial cells lose their homeostatic functions. Direct enrichment of the MD signature in the AD brain, however, has so far been demonstrated only in astrocytes, oligodendrocytes, and pericytes, and, in our own reanalysis, in human-induced pluripotent stem cell (hiPSC)-derived neural progenitor cells carrying an APP mutation; we distinguish this evidence from observations documenting identity loss or a reactive state alone. We further caution that the novel cell populations identified in recent single-cell transcriptomic studies should not be assumed to represent genuinely new cell types: such clusters may equally reflect a blurring of existing cell lineages, or technical artifacts that produce the same appearance. A drifting transcriptomic profile also does not always signify a corresponding physiological change. These possibilities warrant careful attention, and we therefore emphasize the critical need to integrate transcriptomic data with in vivo functional and morphological validation. This integration is essential to determine whether these identity shifts contribute to AD progression or merely reflect underlying epigenetic instability. [BMB Reports 2026; 59(9): 407-417]</description>
    <dc:date>2026-08-31T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/57680">
    <title>Engineering a membrane protein chaperone to ameliorate the proteotoxicity of mutant huntingtin</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/57680</link>
    <description>Title: Engineering a membrane protein chaperone to ameliorate the proteotoxicity of mutant huntingtin
Author(s): Oh, Jeonghyun; Catherine, Christy; Kim, Eun Seon; Min, Kwang Wook; Jeong, Hae Chan; Kim, Hyojin; Kim, Mijin; Ahn, Seung Hae; Lukianenko, Nataliia; Jo, Min Gu; Bak, Hyeon Seok; Lim, Sungsu; Kim, Yun Kyung; Kim, Ho Min; Lee, Sung Bae; Cho, Hyunju
Abstract: Toxic protein aggregates are associated with various neurodegenerative diseases, including Huntington&amp;apos;s disease (HD). Since no current treatment delays the progression of HD, we develop a mechanistic approach to prevent mutant huntingtin (mHttex1) aggregation. Here, we engineer the ATP-independent cytosolic chaperone PEX19, which targets peroxisomal membrane proteins to peroxisomes, to remove mHttex1 aggregates. Using yeast toxicity-based screening with a random mutant library, we identify two yeast PEX19 variants and engineer equivalent mutations into human PEX19 (hsPEX19). These variants effectively delay mHttex1 aggregation in vitro and in cellular HD models. The mutated hydrophobic residue in the alpha 4 helix of hsPEX19 variants binds to the N17 domain of mHttex1, thereby inhibiting the initial aggregation process. Overexpression of the hsPEX19-FV variant rescues HD-associated phenotypes in primary striatal neurons and in Drosophila. Overall, our data reveal that engineering ATP-independent membrane protein chaperones is a promising therapeutic approach for rational targeting of mHttex1 aggregation in HD.</description>
    <dc:date>2024-12-31T15:00:00Z</dc:date>
  </item>
</rdf:RDF>

